Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

By T. Hideshima, C. Mitsiades, M. Akiyama, Toshiaki Hayashi, D. Chauhan, P. Richardson, R. Schlossman, K. Podar, N. Munshi, N. Mitsiades and 1 more. Blood, 2003

602 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/080ffec7fd22869f667aeb9e7644bea907b02580

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. J. Adams
2. S. Rajkumar

In Molecular Biology

1. J. Adams
2. P. Richardson
3. T. Hideshima
4. S. Rajkumar
5. A. Kinghorn
6. Marcy J. Balunas

In Oncology

1. J. Adams
2. S. Rajkumar
3. A. Kinghorn
4. Marcy J. Balunas

Citations in the corpus

• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007, background): “For example, gene and protein profiling of bortezomib-treated multiple myeloma cells shows cleavage of DNA repair enzyme”
• The proteasome: a suitable antineoplastic target (2004, positive): “Further investigation of how bortezomib mediates its effects against multiple myeloma has confirmed that, at least in vitro , bortezomib induces caspase expressio”